Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers

AACR 2020

Published: 30 Jul 2020

Views: 582

Rating:

Save

Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA

Dr Mark Yarchoan speaks to ecancer in an online interview for the virtual AACR 2020 meeting.

He discusses the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study into atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers.

Dr Yarchoan details some background to biliary tract cancers before explaining the design of the trial and what results were seen.

He concluded by stating that the combination was promising, as it met its primary endpoint for progression free survival, however the low response rates highlight the challenge of immunotherapy in this tumour type.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Highlights in melanoma from ASCO 2024

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

Highlights in melanoma from ASCO 2024 ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

More from ecancer